NEOPROBE CORP
15-12G, 1996-12-23
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Previous: AMERICAN AADVANTAGE FUNDS, NSAR-B, 1996-12-23
Next: NEOPROBE CORP, 8-A12G/A, 1996-12-23



<PAGE>   1

                       SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549


                                     FORM 15


     Certification and Notice of Termination of Registration under Section 12(g)
       of the Securities Exchange Act of 1934 or Suspension of Duty to File
       Reports Under Sections 13 and 15(d) of the Securities Exchange Act of
       1934.

                                            Commission File No.        26520
                                                                ---------------

                              Neoprobe Corporation
- --------------------------------------------------------------------------------
             (Exact name of registrant as specified in its charter)

       425 Metro Place North, Suite 400, Dublin, OH 43017 - (614) 793-7500
- --------------------------------------------------------------------------------
    (Address, including zip code, and telephone number, including area code,
                  of registrant's principal executive offices)


                Class E Redeemable Common Stock Purchase Warrants
          Units consisting of One Share of Common Stock and One Warrant
- --------------------------------------------------------------------------------
            (Title of each class of securities covered by this Form)


                     Common Stock, par value $.001 per share
                          Rights to Purchase Series A
                         Junior Participating Preferred
                        Stock, par value $.001 per share
- --------------------------------------------------------------------------------
         (Titles of all other classes of securities for which a duty to
               file reports under Section 13(a) or 15(d) remains)

     Please place an X in the box(es) to designate the appropriate rule
provision(s) relied upon to terminate or suspend the duty to file reports:

                Rule 12g-4(a)(1)(i)    [X]         Rule 12h-3(b)(1)(ii)   [ ]
                Rule 12g-4(a)(1)(ii)   [ ]         Rule 12h-3(b)(2)(i)    [ ]
                Rule 12g-4(a)(2)(i)    [ ]         Rule 12h-3(b)(2)(ii)   [ ]
                Rule 12g-4(a)(2)(ii)   [ ]          Rule 15d-6            [ ]
                Rule 12h-3(b)(1)(i)    [ ]

     Approximate number of holders of record as of the certification or notice 
date:
           - 0 -
    -------------------

     Pursuant to the requirements of the Securities Exchange Act of 1934,
Neoprobe Corporation has caused this certification/notice to be signed on its
behalf by the undersigned duly authorized person.


DATE:    December 19, 1996                 BY: s/ David C. Bupp
         -----------------                    ---------------------------------
                                              David C. Bupp, President



© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission